This phase III trial is comparing the effectiveness of giving immunotherapy (PD-1 inhibitors) intermittently as opposed to continuously, for the treatment of metastatic melanoma.
This trial is treating patients with Metastatic Melanoma.
This is a systemic trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Canadian Cancer Trials Group
Other Non-Commercial Sponsor
Melanoma and Skin Cancer Trials Limited
Patients eligible to participate in this study will receive a government funded PD-1 inhibitor either administered continuously, or intermittently.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More